The RGS22 (Regulator of G-protein Signaling 22) antibody is a tool used to detect and study the RGS22 protein, a member of the RGS family that modulates G-protein-coupled receptor (GPCR) signaling by accelerating GTP hydrolysis in Gα subunits, thereby terminating downstream signals. RGS22 is notably expressed in tissues like the testis, immune cells, and certain cancers, where it may influence cellular processes such as proliferation, apoptosis, and metastasis. Research highlights its potential role in tumorigenesis, particularly in prostate, gastric, and colorectal cancers, where altered RGS22 expression correlates with disease progression or therapeutic resistance. The RGS22 antibody enables investigations into its expression patterns, subcellular localization, and interactions via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Its development supports both basic research—unraveling RGS22's physiological functions—and clinical studies exploring its diagnostic or prognostic value in oncology. However, challenges remain in validating antibody specificity and understanding context-dependent roles of RGS22 across different tissues or cancer types. Ongoing studies aim to clarify its regulatory mechanisms and therapeutic potential, positioning RGS22 as a promising target for cancer biomarker discovery or precision medicine strategies.